Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized double-blind placebo-controlled study of meglumine ginkgolide injection in acute ischemic stroke
CTR20191197Phase 2Active
- Sponsor
- Jiangsu Kanion Pharmaceutical Co., Ltd.
- Start
- Jun 2019
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of meglumine ginkgolide injection in ischemic stroke, sponsored by Jiangsu Kanion Pharmaceutical Co., Ltd.. Started Jun 2019; status: active.
02
Drugs
meglumine ginkgolide injection
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on CTR20191197.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20191197.